e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Acute and chronic lung diseases: good clinical practice
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Are there any predictors of MTX response in progressive pulmonary sarcoidosis?
Anna Goljan Geremek (Warsaw, Poland), Anna Goljan Geremek, Michal Bednarek, Urszula Demkow, Elzbieta Puscinska, Adam Nowinski, Dorota Gorecka
Source:
International Congress 2015 – Acute and chronic lung diseases: good clinical practice
Session:
Acute and chronic lung diseases: good clinical practice
Session type:
Thematic Poster Session
Number:
3691
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Anna Goljan Geremek (Warsaw, Poland), Anna Goljan Geremek, Michal Bednarek, Urszula Demkow, Elzbieta Puscinska, Adam Nowinski, Dorota Gorecka. Are there any predictors of MTX response in progressive pulmonary sarcoidosis?. Eur Respir J 2015; 46: Suppl. 59, 3691
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015
Unusual multisystemic relapse of sarcoidosis after corticosteroids withdrawal
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
TNF-α polymorphism as a prognostic marker for MTX efficacy in progressive pulmonary sarcoidosis
Source: International Congress 2016 – Sarcoidosis
Year: 2016
Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Negative outcome of prednisone in possible idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
Role of infliximab in managing resistant ventricular arrhythmias in sarcoidosis
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015
Steroid treatment effect in pulmonary sarcoidosis (STEPS study)
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Systemic inflammation in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Prognostic significance of selected biomarkers in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Lymphangioma in patients with pulmonary lymphangioleiomyomatosis – Results of sirolimus treatment
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
Sarcoidosis
Source: Respipedia Article
Year: 2017
Significant changes in monocyte subsets during infliximab therapy in severe sarcoidosis
Source: International Congress 2015 – Sarcoidosis: pathogenesis
Year: 2015
Sarcoidosis: Changed phenotype and worsening of the course by overtime
Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice
Year: 2015
Childhood pulmonary sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept